Gastritis

Gastritis Evaluation and Initial Treatment

Gastritis is treated based on the most likely cause, most commonly Helicobacter pylori infection, medication-related injury (especially NSAIDs/aspirin), and autoimmune or bile-associated injury. Symptom-based “dyspepsia” evaluation uses noninvasive H. pylori testing and targeted therapy for low-risk patients according to the ACG/CAG dyspepsia guideline [1].

Cause-Based Diagnostic Framework

The most actionable clinical task is identifying treatable etiologies that change management.

H. pylori infection should be evaluated in dyspepsia syndromes without prior investigation [1].
Medication-associated mucosal injury should be assessed for current or recent NSAID and aspirin exposure because ongoing exposure drives recurrence risk [2].
Autoimmune gastritis should be considered when pernicious anemia or related nutritional deficiencies are present, because management requires long-term follow-up (diagnostic confirmation typically via endoscopy with biopsy and serology in practice).
Alarm features and high cancer-risk populations should prompt earlier endoscopic evaluation rather than empiric symptomatic therapy [1].

Medication Selection Algorithm

Acid suppression treats symptoms but does not eradicate H. pylori or medication-caused injury.

If H. pylori infection is confirmed, eradication therapy should be initiated using recommended first-line regimens.
Bismuth quadruple therapy (a PPI plus bismuth plus tetracycline plus metronidazole) is recommended as first-line treatment in treatment-naïve patients [3].
Clarithromycin-containing triple therapy should be avoided in populations with suspected clarithromycin resistance or prior macrolide exposure [3].
If H. pylori is negative or symptoms persist after eradication, proton pump inhibitor (PPI) therapy is recommended for uninvestigated dyspepsia [1].

Treatment Initiation Thresholds

Noninvasive initial management is guided by cancer-risk and alarm features.

Endoscopy is not routinely suggested for dyspepsia patients under age 60 solely to exclude malignancy when alarm features are absent [1].
In dyspepsia patients <60 years without alarm features, a noninvasive H. pylori test with treatment if positive is recommended [1].
In H. pylori-negative patients or in those who remain symptomatic after eradication, empiric PPI therapy is recommended [1].

Monotherapy Versus Combination Therapy

Combination therapy is required when H. pylori eradication is targeted.

Symptom control in dyspepsia/gastritis can be addressed with PPI monotherapy when no H. pylori eradication is planned [1].
H. pylori eradication uses combination antibiotic therapy plus acid suppression.
Bismuth quadruple therapy is a combination regimen and is recommended as first-line therapy [3].

Key Evidence Supporting This Approach

“Test-and-treat” strategies improve outcomes compared with empiric acid suppression in uninvestigated dyspepsia.

In uninvestigated dyspepsia, a H. pylori test-and-treat approach is supported by evidence showing reduced persistent dyspepsia with test-and-treat versus empiric acid suppression (relative risk ~0.59) [4].
For eradication, adherence to guideline-recommended first-line regimens is supported by guideline synthesis.
Bismuth quadruple therapy for 14 days is recommended as first-line treatment in treatment-naïve patients [3].

Common Pitfalls to Avoid

In real-world practice, several failure modes lead to persistent symptoms.

PPI-only strategies without H. pylori testing can miss a treatable cause of chronic gastritis/dyspepsia [1].
Empiric treatment with clarithromycin-containing regimens can fail when clarithromycin resistance is prevalent.
Guideline recommendations restrict clarithromycin triple therapy to appropriately selected settings [3].
Continuing NSAID/aspirin exposure after mucosal injury treatment increases recurrence risk and undermines durable symptom improvement [5].

Target Goals of Therapy

Therapy targets cause-specific outcomes and symptom resolution.

For H. pylori gastritis/dyspepsia, the goal is successful eradication using recommended regimens [3].
For ongoing dyspepsia symptoms without an active eradication plan, PPI therapy is used to improve symptoms in uninvestigated presentations after H. pylori strategy completion [1].

When to Escalate to Endoscopy

Escalation is driven by risk stratification rather than the label “gastritis.”

Endoscopy should be considered for patients with dyspepsia who have alarm features or high cancer-risk characteristics instead of relying on noninvasive therapy alone [1].
Patients with persistent symptoms despite guideline-based initial management should undergo reassessment for alternate diagnoses, including structural causes requiring endoscopy [1].